Successful outcomes for inflammatory bowel disease
Our gastroenterology physicians are founding members of ImproveCareNow, a national collaborative committed to improving the care and quality of life for youngsters with inflammatory bowel disease. We use a national database to track our outcomes, remission rates, complications, drug usage and other variables.
We have enrolled more than 300 children in our studies and have seen an increase in our remission rate from 54 to 70 percent. The percentage of children with severe Crohn's disease has decreased. And the percentage of our Crohn's disease pediatric patients on steroids is extremely low.
Ongoing research
We actively participate in research efforts for inflammatory bowel disease with the ImproveCareNow collaborative. In addition, Inova's pediatric gastroenterology research includes:
- Activation factors in inflammatory bowel disease
- Eosinophilic esophagitis
- GERD
- Long-term use of biologic therapies in inflammatory bowel disease
- Neonatal GERD
